Compare Enveric Biosciences Inc (ENVB) vs Quanta Services Inc (PWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Quanta Services Inc — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Quanta Services Inc trades at $691.5 (market cap $105.40B). The key difference: Quanta Services Inc is far larger — about 15754.9× Enveric Biosciences Inc's market cap, and Quanta Services Inc pays a 0.06% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Quanta Services Inc for 62 Days on average.
| ENVB | PWR | |
|---|---|---|
Market Cap | $6.69M | $105.40B |
Volume | 41,141 | 1,014,408 |
Sector | Health | Industrials |
52-Week High | $10.80 | $785.24 |
52-Week Low | $1.27 | $412.21 |
Typical Hold Time | 14 Days | 62 Days |
Enterprise Value | -$1.60M | $111.50B |
Dividend Yield | — | 0.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Quanta Services (PWR) trades at $685.33, down 4.76% on the day, but maintains a bullish technical trend with strong analyst support. Revenue growth is robust, climbing from $17.1B in 2022 to $28.5B in 2025, with net income reaching $1.03B. The company benefits from a record $53B backlog and positive earnings surprises, though valuation multiples like a P/E of 80.21 suggest premium pricing. Recent news highlights PWR's role in AI infrastructure and data center spending, driving investor optimism.
Outlook remains positive given strong earnings beats and sector tailwinds, but high valuation and execution risks from rapid expansion pose challenges. Analysts see 26.5% upside to a $802.08 consensus target, with no sell ratings. Risks include margin pressure and macroeconomic sensitivity, yet institutional bullishness and operational momentum support long-term growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →
